Natera and Aveta Biomics bring Signatera into APG-157 Phase 3 head and neck cancer trial
See how Natera’s Signatera could sharpen APG-157’s Phase 3 evidence in head and neck cancer and what risks remain. Read the analysis.
See how Natera’s Signatera could sharpen APG-157’s Phase 3 evidence in head and neck cancer and what risks remain. Read the analysis.